Meltem Zeytinoglu is an Endocrinology/Metabolic physician affiliated with Eli Lilly. OpenAlex indexes 27 publications with 343 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9977 Woods Dr
Skokie, IL 600771057
Telephone
847-663-8540Provider last certified this registry record 16 Dec 2025.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- Novo Nordisk IncProgram year20221 payment
- Novo Nordisk IncProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
55.4%Insulin Analog20%Lantus Solostar100%Part D<11 patientsGLP-1 receptor agonist18.5%Victoza 3-Pak100%Part D<11 patients+ 1 more class in this area
Hormonal (systemic)
26.2%l-Thyroxine26.2%Levothyroxine Sodium100%Part D≥12 patientsCardiovascular
18.5%Statin18.5%Atorvastatin Calcium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes
Annals of Internal Medicine
2026 - Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review
Diabetes Obesity and Metabolism
2025 - Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)
The Journal of Clinical Endocrinology & Metabolism
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Mark Bangs, MD
Eli Lilly
David Alan Cox
Eli Lilly
Heidi Crane
Eli Lilly
Mike Hutton
Eli Lilly
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”